{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:28:16Z","timestamp":1794493696755,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with epidermal growth factor receptor (<jats:italic>EGFR<\/jats:italic>)-mutated non-small cell lung cancer (NSCLC) often develop resistance to current standard third-generation EGFR tyrosine kinase inhibitors (TKIs); no targeted treatments are approved in the osimertinib-relapsed setting. In this open-label, dose-escalation and dose-expansion phase 1 trial, the potential for improved anti-tumor activity by combining amivantamab, an EGFR-MET bispecific antibody, with lazertinib, a third-generation EGFR TKI, was evaluated in patients with <jats:italic>EGFR<\/jats:italic>-mutant NSCLC whose disease progressed on third-generation TKI monotherapy but were chemotherapy naive (CHRYSALIS cohort E). In the dose-escalation phase, the recommended phase 2 combination dose was established; in the dose-expansion phase, the primary endpoints were safety and overall response rate, and key secondary endpoints included progression-free survival and overall survival. The safety profile of amivantamab and lazertinib was generally consistent with previous experience of each agent alone, with 4% experiencing grade \u22653 events; no new safety signals were identified. In an exploratory cohort of 45 patients who were enrolled without biomarker selection, the primary endpoint of investigator-assessed overall response rate was 36% (95% confidence interval, 22\u201351). The median duration of response was 9.6\u2009months, and the median progression-free survival was 4.9\u2009months. Next-generation sequencing and immunohistochemistry analyses identified high EGFR and\/or MET expression as potential predictive biomarkers of response, which will need to be validated with prospective assessment. ClinicalTrials.gov identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02609776\">NCT02609776<\/jats:ext-link>.<\/jats:p>","DOI":"10.1038\/s41591-023-02554-7","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T16:03:52Z","timestamp":1694707432000},"page":"2577-2585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-7132","authenticated-orcid":false,"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6859-363X","authenticated-orcid":false,"given":"Jorge E.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Haura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-6054","authenticated-orcid":false,"given":"Rachel E.","family":"Sanborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-7101","authenticated-orcid":false,"given":"Anna","family":"Minchom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Youn","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua K.","family":"Sabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1764-4975","authenticated-orcid":false,"given":"Sai-Hong Ignatius","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Bauml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Roshak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Thayu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E.","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4846-7449","authenticated-orcid":false,"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"2554_CR1","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/onc.2009.198","volume":"28","author":"AF Gazdar","year":"2009","unstructured":"Gazdar, A. F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28, S24\u2013S31 (2009).","journal-title":"Oncogene"},{"key":"2554_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","volume":"4","author":"S Vyse","year":"2019","unstructured":"Vyse, S. & Huang, P. H. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct. Target. Ther. 4, 5 (2019).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2554_CR3","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380\u20132388 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2554_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947\u2013957 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2554_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239\u2013246 (2012).","journal-title":"Lancet Oncol."},{"key":"2554_CR6","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist, L. V. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327\u20133334 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2554_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735\u2013742 (2011).","journal-title":"Lancet Oncol."},{"key":"2554_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","volume":"36","author":"SS Ramalingam","year":"2018","unstructured":"Ramalingam, S. S. et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J. Clin. Oncol. 36, 841\u2013849 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2554_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2554_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2554_CR11","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 23, 1167\u20131179 (2022).","journal-title":"Lancet Oncol."},{"key":"2554_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti, A. et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer 121, 725\u2013737 (2019).","journal-title":"Br. J. Cancer"},{"key":"2554_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","volume":"147","author":"S Schmid","year":"2020","unstructured":"Schmid, S., Li, J. J. N. & Leighl, N. B. Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer 147, 123\u2013129 (2020).","journal-title":"Lung Cancer"},{"key":"2554_CR14","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","volume":"4","author":"GR Oxnard","year":"2018","unstructured":"Oxnard, G. R. et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 4, 1527\u20131534 (2018).","journal-title":"JAMA Oncol."},{"key":"2554_CR15","doi-asserted-by":"publisher","first-page":"viii741","DOI":"10.1093\/annonc\/mdy424.064","volume":"29","author":"VA Papadimitrakopoulou","year":"2018","unstructured":"Papadimitrakopoulou, V. A. et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann. Oncol. 29, viii741 (2018).","journal-title":"Ann. Oncol."},{"key":"2554_CR16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560\u2013562 (2015).","journal-title":"Nat. Med."},{"key":"2554_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.21037\/tlcr.2016.12.02","volume":"5","author":"R Minari","year":"2016","unstructured":"Minari, R., Bordi, P. & Tiseo, M. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. Transl. Lung Cancer Res. 5, 695\u2013708 (2016).","journal-title":"Transl. Lung Cancer Res."},{"key":"2554_CR18","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1158\/1078-0432.CCR-15-1915","volume":"22","author":"S Ortiz-Cuaran","year":"2016","unstructured":"Ortiz-Cuaran, S. et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin. Cancer Res. 22, 4837\u20134847 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2554_CR19","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","volume":"24","author":"Z Yang","year":"2018","unstructured":"Yang, Z. et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin. Cancer Res. 24, 3097\u20133107 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2554_CR20","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.xcrm.2020.100007","volume":"1","author":"N Roper","year":"2020","unstructured":"Roper, N. et al. Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep. Med 1, 100007 (2020).","journal-title":"Cell Rep. Med"},{"key":"2554_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger, D. S. et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J. NatlCompr. Canc. Netw. 20, 497\u2013530 (2022).","journal-title":"J. NatlCompr. Canc. Netw."},{"key":"2554_CR22","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/annonc\/mdu123","volume":"25","author":"B Besse","year":"2014","unstructured":"Besse, B. et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line\/second and further lines of treatment in advanced disease. Ann. Oncol. 25, 1475\u20131484 (2014).","journal-title":"Ann. Oncol."},{"key":"2554_CR23","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1200\/JCO.20.03570","volume":"39","author":"NH Hanna","year":"2021","unstructured":"Hanna, N. H. et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J. Clin. Oncol. 39, 1040\u20131091 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2554_CR24","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","volume":"76","author":"SL Moores","year":"2016","unstructured":"Moores, S. L. et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 76, 3942\u20133953 (2016).","journal-title":"Cancer Res."},{"key":"2554_CR25","doi-asserted-by":"publisher","first-page":"100641","DOI":"10.1016\/j.jbc.2021.100641","volume":"296","author":"J Neijssen","year":"2021","unstructured":"Neijssen, J. et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J. Biol. Chem. 296, 100641 (2021).","journal-title":"J. Biol. Chem."},{"key":"2554_CR26","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","volume":"19","author":"S Vijayaraghavan","year":"2020","unstructured":"Vijayaraghavan, S. et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis. Mol. Cancer Ther. 19, 2044\u20132056 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"2554_CR27","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","volume":"10","author":"J Yun","year":"2020","unstructured":"Yun, J. et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov. 10, 1194\u20131209 (2020).","journal-title":"Cancer Discov."},{"key":"2554_CR28","doi-asserted-by":"publisher","first-page":"9009","DOI":"10.1200\/JCO.2019.37.15_suppl.9009","volume":"37","author":"EB Haura","year":"2019","unstructured":"Haura, E. B. et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 37, 9009 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2554_CR29","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1200\/JCO.2022.40.16_suppl.9008","volume":"40","author":"M Krebs","year":"2022","unstructured":"Krebs, M. et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: updated results from the CHRYSALIS study. J. Clin. Oncol. 40, 9008 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2554_CR30","unstructured":"RYBREVANT (amivantamab-vmjw) injection, for intravenous use [prescribing information]. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/RYBREVANT-pi.pdf (Janssen Biotech, Inc., 2021)."},{"key":"2554_CR31","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park, K. et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J. Clin. Oncol. 39, 3391\u20133402 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2554_CR32","doi-asserted-by":"publisher","first-page":"S874","DOI":"10.1016\/j.jtho.2021.08.084","volume":"16","author":"A Spira","year":"2021","unstructured":"Spira, A. et al. OA15.03 Amivantamab in non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutation: initial results from CHRYSALIS. J. Thorac. Oncol. 16, S874\u2013S875 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2554_CR33","doi-asserted-by":"publisher","first-page":"S951","DOI":"10.1016\/j.annonc.2021.08.1797","volume":"32","author":"NB Leighl","year":"2021","unstructured":"Leighl, N. B. et al. 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: analysis from the CHRYSALIS study. Ann. Oncol. 32, S951\u2013S952 (2021).","journal-title":"Ann. Oncol."},{"key":"2554_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon, E. B. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384, 665\u2013673 (2014).","journal-title":"Lancet"},{"key":"2554_CR35","doi-asserted-by":"publisher","first-page":"S808","DOI":"10.1016\/j.annonc.2022.08.054","volume":"33","author":"J Mazieres","year":"2022","unstructured":"Mazieres, J. et al. Tepotinib+osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: initial results from the INSIGHT 2 study. Ann. Oncol. 33, S808\u2013S869 (2022).","journal-title":"Ann. Oncol."},{"key":"2554_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"LV Sequist","year":"2020","unstructured":"Sequist, L. V. et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 21, 373\u2013386 (2020).","journal-title":"Lancet Oncol."},{"key":"2554_CR37","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","volume":"20","author":"MJ Ahn","year":"2019","unstructured":"Ahn, M. J. et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1\u20132 study. Lancet Oncol. 20, 1681\u20131690 (2019).","journal-title":"Lancet Oncol."},{"key":"2554_CR38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jtho.2021.11.025","volume":"17","author":"BC Cho","year":"2022","unstructured":"Cho, B. C. et al. A phase 1\/2 study of lazertinib 240 mg in patients with advanced EGFR T790M-positive NSCLC after previous EGFR tyrosine kinase inhibitors. J. Thorac. Oncol. 17, 558\u2013567 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"2554_CR39","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.annonc.2022.10.350","volume":"33","author":"TSK Mok","year":"2022","unstructured":"Mok, T. S. K. et al. Nivolumab (NIVO)+ chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722. Ann. Oncol. 33, 1560\u20131597 (2022).","journal-title":"Ann. Oncol."},{"key":"2554_CR40","doi-asserted-by":"crossref","unstructured":"Lee, S. H. et al. Amivantamab and lazertinib in treatment-na\u00efve EGFR-mutated advanced non\u2013small-cell lung cancer (NSCLC): long-term follow-up and ctDNA results from CHRYSALIS. J. Clin. Oncol. 41, https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2023.41.16_suppl.9134 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.9134"},{"key":"2554_CR41","doi-asserted-by":"publisher","unstructured":"Cho, B. C. et al. 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation EGFR tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.1572 (2020).","DOI":"10.1016\/j.annonc.2020.08.1572"},{"key":"2554_CR42","doi-asserted-by":"publisher","first-page":"9006","DOI":"10.1200\/JCO.2022.40.16_suppl.9006","volume":"40","author":"CA Shu","year":"2022","unstructured":"Shu, C. A. et al. Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: updated results from CHRYSALIS-2. J. Clin. Oncol. 40, 9006 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2554_CR43","doi-asserted-by":"publisher","first-page":"S981","DOI":"10.1016\/j.annonc.2021.08.1852","volume":"32","author":"K Park","year":"2021","unstructured":"Park, K. et al. Management of infusion-related reactions (IRRs) in patients receiving amivantamab. Ann. Oncol. 32, S981\u2013S982 (2021).","journal-title":"Ann. Oncol."},{"key":"2554_CR44","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1038\/onc.2009.197","volume":"28","author":"T John","year":"2009","unstructured":"John, T., Liu, G. & Tsao, M. S. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 28, S14\u2013S23 (2009).","journal-title":"Oncogene"},{"key":"2554_CR45","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.jtho.2019.06.009","volume":"14","author":"R Guo","year":"2019","unstructured":"Guo, R. et al. MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the Lung Cancer Mutation Consortium. J. Thorac. Oncol. 14, 1666\u20131671 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"2554_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(11)70318-7","volume":"13","author":"R Pirker","year":"2012","unstructured":"Pirker, R. et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 13, 33\u201342 (2012).","journal-title":"Lancet Oncol."},{"key":"2554_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.lungcan.2013.07.016","volume":"82","author":"J Mazieres","year":"2013","unstructured":"Mazieres, J. et al. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer 82, 231\u2013237 (2013).","journal-title":"Lung Cancer"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02554-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02554-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02554-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T10:05:09Z","timestamp":1697450709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02554-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2554"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02554-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.C.C.: consulting or advisory role (Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Bristol Myers Squibb, Ono Pharmaceutical, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, Merck Sharp & Dohme, Medpacto, Blueprint Medicines, KANAPH Therapeutics, BridgeBio, Cyrus Therapeutics, Guardant Health and Oscotec); board of directors (Interpark Bio Convergence and J INTS BIO); research funding (Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono Pharmaceutical, Dizal Pharma, Merck Sharp & Dohme, AbbVie, Medpacto, GI Innovation, Eli Lilly, Blueprint Medicines and Interpark Bio Convergence); royalties (Champions Oncology); stock ownership (TheraCanVac, Gencurix, BridgeBio, KANAPH Therapeutics, Cyrus Therapeutics, Interpark Bio Convergence and J INTS BIO); founder (DAAN Biotherapeutics). D.-W.K.: travel, accommodations and expenses (Daiichi Sankyo and Amgen); research funding to institution (Alpha Biopharma, AstraZeneca\/MedImmune, Hanmi, Janssen, Merus, Mirati Therapeutics, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche\/Genentech, Takeda, TP Therapeutics, Xcovery, Yuhan, Boehringer Ingelheim, Amgen and Daiichi Sankyo). A.I.S.: consulting or advisory role (Incyte, Amgen, Novartis, AstraZeneca\/MedImmune, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Takeda and Janssen); consulting or advisory role for institution (Array BioPharma, AstraZeneca\/MedImmune, Merck and Bristol Myers Squibb); stock ownership (Eli Lilly); honoraria (CytomX Therapeutics, AstraZeneca\/MedImmune, Merck, Takeda, Amgen, Janssen, Novartis, Bristol Myers Squibb and Bayer); research funding (LAM Therapeutics); research funding to institution (Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Newlink Genetics, Incyte, AbbVie, Ignyta, LAM Therapeutics, Trovagene, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol Myers Squibb, LOXO Oncology, Arch Therapeutics, Gritstone Oncology, Plexxikon, Amgen, Daiichi Sankyo, ADC Therapeutics, Janssen, Mirati Therapeutics, Rubius and Synthekine); leadership role for institution (NEXT Oncology Virginia). J.E.G.: consulting or advisory role (AstraZeneca and Atara Biotherapeutics); honoraria (Bristol Myers Squibb and Celgene); speakers\u2019 bureau (Bristol Myers Squibb); research funding to institution (Janssen); travel, accommodations and expenses (Atara Biotherapeutics, Bristol Myers Squibb and Celgene). E.B.H.: consulting or advisory role (Janssen, Revolution Medicines, and Ellipses Pharmaceuticals); research funding to institution (Revolution Medicines). S.-W.K.: consulting or advisory role (AstraZeneca, Eli Lilly, Ono Pharmaceutical, Bristol Myers Squibb, Amgen and Boehringer Ingelheim); speakers\u2019 bureau (Boehringer Ingelheim and Amgen); research funding (AstraZeneca). R.E.S.: consulting or advisory role (AstraZeneca, EMD Serono, Blueprint Medicines, Daiichi Sankyo, Eli Lilly, Janssen Oncology, Macrogenics, Sanofi Aventis, Regeneron and Mirati Therapeutics); travel, accommodations and expenses (AstraZeneca); honoraria (AstraZeneca and Amgen); research funding to institution (Bristol Myers Squibb and MedImmune); research funding (Merck and AstraZeneca). E.K.C.: no relationships to disclose. K.H.L.: no relationships to disclose. A.M.: consulting or advisory boards (Janssen, Merck, Takeda, GSK and Genmab); honoraria (Chugai, Novartis Oncology, Faron Pharmaceuticals, Bayer and Janssen); expenses (Amgen and LOXO Oncology). J.-S.L.: consulting or advisory role (AstraZeneca and Ono Pharmaceutical). J.-Y.H.: consulting or advisory role (MSD Oncology, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Novartis, Takeda and Pfizer); honoraria (Roche, AstraZeneca, Bristol Myers Squibb and Takeda); research funding (Roche, Pfizer, Ono Pharmaceutical and Takeda). M.N.: consulting or advisory role (AstraZeneca, Caris Life Sciences, Daiichi Sankyo, Takeda, Novartis, EMD Serono, Pfizer, Eli Lilly, Genentech and Janssen); speakers\u2019 bureau (Takeda and Blueprint Medicines); travel support (AnHeart Therapeutics). J.K.S.: consulting or advisory role (AstraZeneca, Janssen Oncology, Navire, Pfizer, Regeneron, Medscape and Takeda). S.-H.I.O.: advisory role (Elevation Oncology); stock ownership (Turning Point Therapeutics and Elevation Oncology); honorarium (Pfizer); advisory fees (BeiGene, Roche\/Genentech, AstraZeneca, Takeda\/ARIAD, Pfizer, Caris Life Science, Janssen, Daiichi Sankyo and Eli Lilly). P.L., J.M.B., J.C.C., A.R., G.G., J.X., M.T. and R.E.K.: employment and stock ownership (Johnson & Johnson). K.P.: consulting or advisory role (AstraZeneca, Eli Lilly, Ono Pharmaceutical, Bristol Myers Squibb, Merck Sharp & Dohme, Blueprint Medicines, Amgen, Merck, LOXO Oncology, AbbVie, Daiichi Sankyo, Boehringer Ingelheim, Johnson & Johnson, Eisai and Puma Biotechnology); speakers\u2019 bureau (Boehringer Ingelheim and AZD); and research funding (AstraZeneca and Merck Sharp & Dohme).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}